The FDA this month warned Valeant Pharmaceuticals (NYSE:VRX) on violations found during inspections of its Rochester, N.Y., plant last summer.
The federal safety watchdog, in a Nov. 3 warning letter posted online today, wrote that inspections from Aug. 23 through Sept. 1 turned up problems with its small-particle aerosol generator, the SPAG-2 device, and a high-precision compound and dispensing pen, the OraPharma OnSet mixing pen.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA warns Valeant on SPAG-2 nebulizer, OraPharma OnSet mixing pen appeared first on MassDevice.